Fresenius: Jefferies ups target price

(CercleFinance.com) - Jefferies has raised its target price for Fresenius shares, citing the German healthcare group's decision to invest "now" to obtain growth "later.
"

2019 will be a year of investment in both Kabi, Fresenius' biosimilar unit, and Helios, its hospitals division, the broker said in a note, while maintaining a "hold" rating on the stock.

On Thursday, Fresenius shares were up 0.3% at 48.4 euros, outperforming a 0.1% rise in the DAX index. They have risen by 14% so far this year.

Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.